US5064643A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating sickle cell disease
Assignee: Emory University
•
Filing: 1990-07-25
•
Granted: 1991-11-12
•
Expires: 2010-07-25
Abstract
Abstract In accordance with the present invention, a method is provided for treating sickle cell anemia. The method comprises injecting an effective concentration of a surface active copolymer into the patient with sickle cell anemia. The surface active copolymer can be an ethylene oxide-propylene oxide condensation product with the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight of approximately 950 to 4000, preferably approximately 1200 to 3500, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 50% to 90% by weight of the compound.
Inventors
- 👤 Robert L. Hunter
- 👤 Alexander Duncan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 17:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K31/765; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126; A61K38/00; A61K38/16; A61K38/164; A61K38/166; A61K38/43; A61K38/44; A61K38/446; A61K38/46; A61K38/48; A61K38/49
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
104 words
A method for treating sickle cell anemia in humans comprising the step of injecting into the human with sickle cell anemia a solution containing an anticoagulant and an effective concentration of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 2
Independent Claim
104 words
A method for treating sickle cell anemia in humans comprising the step of injecting into the human with sickle cell anemia a solution containing an anticoagulant and an effective concentration of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 3
Dependent Claim
78 words
The method of claim 1 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 1200 to 3500, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 4
Dependent Claim
50 words
The method of claim 1 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 1750 and the total molecular weight of the compound is approximately 8400.
Claim 5
Independent Claim
102 words
A method for treating sickle cell anemia in humans comprising the step of injecting intravenously into the human with sickle cell anemia a solution with an effective amount of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 6
Independent Claim
102 words
A method for treating sickle cell anemia in humans comprising the step of injecting intravenously into the human with sickle cell anemia a solution with an effective amount of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 7
Dependent Claim
78 words
The method of claim 4 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 1200 to 3500, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 8
Dependent Claim
50 words
The method of claim 4 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 1750 and the total molecular weight of the compound is approximately 8400.
Claim 9
Dependent Claim
12 words
The method of claim 4 wherein the solution also contains an anticoagulant.
Claim 10
Independent Claim
102 words
A method for treating sickle cell anemia in humans comprising the step of injecting intramuscularly into the human with sickle cell anemia a solution with an effective amount of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 11
Independent Claim
102 words
A method for treating sickle cell anemia in humans comprising the step of injecting intramuscularly into the human with sickle cell anemia a solution with an effective amount of a surface active copolymer with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 950 to 4000, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 12
Dependent Claim
78 words
The method of claim 8 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C 3 H 6 O) has a molecular weight of between approximately 1200 to 3500, and b is an integer such that the hydrophile portion represented by (C 2 H 4 O) constitutes between approximately 50% to 90% by weight of the compound.
Claim 13
Dependent Claim
50 words
The method of claim 8 wherein the surface active copolymer has the following formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 1750 and the total molecular weight of the compound is approximately 8400.
Claim 14
Dependent Claim
12 words
The method of claim 8 wherein the solution also contains an anticoagulant.
References Cited (Backward Citations)
GB1183112A
Cited
US3740421A
Cited
US3450502A
Cited
US3641240A
Cited
US3577522A
Cited
US3590125A
Cited
US4073886A
Cited
US3956259A
Cited
US4179337A
Cited
USRE29909E
Cited
USRE29909F1
Cited
JPS525094A
Cited
US4305922A
Cited
US4186253A
Cited
US4609546A
Cited
US4600652A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-11-11 | 1995-05-13 | 1995-11-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-11-11 | 1999-05-13 | 1999-11-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-11-11 | 2003-05-13 | 2003-11-12 | $7700.00 | Window Closed / Lapsed |